Proposed Collection; 60-Day Comment Request; The National Physician Survey of Precision Medicine in Cancer Treatment (NCI), 72077-72078 [2015-29382]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 222 / Wednesday, November 18, 2015 / Notices
Date: December 3, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, Rockville, MD 20852,
(Telephone Conference Call).
Contact Person: Sathasiva B. Kandasamy,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute of Child
Health and Human Development, 6100
Executive Boulevard, Room 5B01, Bethesda,
MD 20892–9304, (301) 435–6680,
skandasa@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Name of Committee: Center for Scientific
Review Special Emphasis Panel, PAR Panel:
Global Infectious Diseases Research Training
Program.
Date: December 11, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The St. Regis Washington, DC, 923
16th Street NW., Washington, DC 20006.
Contact Person: Hilary D Sigmon, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5216,
MSC 7852, Bethesda, MD 20892, (301) 594–
6377, sigmonh@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846-93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 12, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: November 10, 2015.
Sylvia Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–29377 Filed 11–17–15; 8:45 am]
[FR Doc. 2015–29381 Filed 11–17–15; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Eunice Kennedy Shriver National
Institute of Child Health And Human
Development; Notice of Closed
Meeting
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, PAR Panel:
Fogarty HIV Research Training Program for
Low-and Middle-Income Country
Institutions.
Date: December 10, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The St. Regis Washington, DC, 923
16th Street NW., Washington, DC 20006.
Contact Person: Hilary D Sigmon, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5216,
MSC 7852, Bethesda, MD 20892, (301) 594–
6377, sigmonh@csr.nih.gov.
VerDate Sep<11>2014
18:50 Nov 17, 2015
Jkt 238001
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in section 552b(c)(4)
and 552b(c)(6), Title 5 U.S.C., as
amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Maternal and Child
Health in Poor Countries: Evidence From
Randomized Evaluation.
Date: December 9, 2015.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Carla T. Walls, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Eunice Kennedy Shriver National
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
72077
Institute of Child Health and Human
Development, NIH, 6100 Executive
Boulevard, Room 5B01, Bethesda, MD
20892–9304, (301) 435–6898, wallsc@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: November 12, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–29376 Filed 11–17–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment
Request; The National Physician
Survey of Precision Medicine in
Cancer Treatment (NCI)
Summary: In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Cancer Institute, the National
Institutes of Health (NIH) will publish
periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Written comments and/or suggestions
from the public and affected agencies
are invited to address one or more of the
following points: (1) Whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
The quality, utility, and clarity of the
information to be collected; and (4)
Minimize the burden of the collection of
information on those who are to
respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To Submit Comments and For Further
Information: To obtain a copy of the
data collection plans and instruments,
submit comments in writing, or request
more information on the proposed
project, contact: Janet S. de Moor, Ph.D.,
MPH, Project Officer, Division of Cancer
E:\FR\FM\18NON1.SGM
18NON1
72078
Federal Register / Vol. 80, No. 222 / Wednesday, November 18, 2015 / Notices
Control and Population Sciences, 9609
Medical Center Drive, 3E438, MSC
9764, Rockville, MD, 20850 or call nontoll-free number 240–276–6806 or Email
your request, including your address to:
janet.demoor@nih.gov. Formal requests
for additional plans and instruments
must be requested in writing.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Proposed Collection: The National
Physician Survey of Precision Medicine
in Cancer Treatment 0925–NEW,
National Cancer Institute (NCI),
National Institutes of Health (NIH).
Need and Use of Information
Collection: The purpose of this study is
to investigate the current practice of
Non-respondents will be invited to
complete a follow-back survey to share
their reasons for not participating. The
study findings will inform NCI of
relevant issues and concerns relating to
the application of precision medicine to
current and future cancer treatment
patterns and practice. This information
will also inform the development of
new funding initiatives to optimize the
use of precision medicine in cancer
treatment. Additionally, information
collected as part of this survey will be
used to develop physician educational
materials to address barriers to precision
medicine in cancer care delivery.
OMB approval is requested for 2
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
261.
precision medicine in cancer treatment
among medical oncologists in the U.S.
This is a nationally representative
survey designed to assess oncologists’
current and potential use of genomic
testing, to inform the development of
interventions to facilitate optimal use of
genomic testing and to improve patientphysician discussions of the risks,
possible benefits, and uncertainties
surrounding the use of these tests.
Current knowledge of this topic is
limited as there are no nationallyrepresentative studies on this topic to
date. There are only two non-federal
studies two that have examined
physicians’ knowledge and attitudes
regarding somatic genetic and genomic
testing. The survey will be administered
by mail and web to approximately 1,630
oncology physicians across the U.S.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total annual
burden hour
Form name
Type of respondent
Precision Medicine Survey—Pilot
Study.
Precision Medicine Survey—Full
Study.
Follow-back Survey ...........................
Oncology Physicians ........................
175
1
20/60
58
Oncology Physicians ........................
600
1
20/60
200
Oncology Physicians ........................
40
1
5/60
3
Dated: October 28, 2015.
Karla Bailey,
Project Clearance Liaison, NCI, NIH.
[FR Doc. 2015–29382 Filed 11–17–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
asabaliauskas on DSK5VPTVN1PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
18:50 Nov 17, 2015
Jkt 238001
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Innovation for HIV Vaccine
Discovery (R01).
Date: December 10–11, 2015.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3G61, 5601 Fishers Lane, Rockville, MD
20892 (Telephone Conference Call).
Contact Person: Jane K. Battles, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room # 3F30B, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20852–9823, (240) 669–5029,
battlesja@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 12, 2015.
Natasha Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–29380 Filed 11–17–15; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse
Amended; Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute on
Drug Abuse Special Emphasis Panel,
November 13, 2015, 01:00 p.m. to
November 13, 2015, 05:00 p.m.,
National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD, 20852 which
was published in the Federal Register
on October 22, 2015, 80 FR 64428.
The date of the meeting was changed
to December 1, 2015. The meeting is
closed to the public.
Dated: November 12, 2015.
Natasha Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–29379 Filed 11–17–15; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
PO 00000
Frm 00039
Fmt 4703
Sfmt 9990
E:\FR\FM\18NON1.SGM
18NON1
]]>Agencies
[Federal Register Volume 80, Number 222 (Wednesday, November 18, 2015)]
[Notices]
[Pages 72077-72078]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-29382]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment Request; The National
Physician Survey of Precision Medicine in Cancer Treatment (NCI)
Summary: In compliance with the requirement of Section
3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity
for public comment on proposed data collection projects, the National
Cancer Institute, the National Institutes of Health (NIH) will publish
periodic summaries of proposed projects to be submitted to the Office
of Management and Budget (OMB) for review and approval.
Written comments and/or suggestions from the public and affected
agencies are invited to address one or more of the following points:
(1) Whether the proposed collection of information is necessary for the
proper performance of the function of the agency, including whether the
information will have practical utility; (2) The accuracy of the
agency's estimate of the burden of the proposed collection of
information, including the validity of the methodology and assumptions
used; (3) The quality, utility, and clarity of the information to be
collected; and (4) Minimize the burden of the collection of information
on those who are to respond, including the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology.
To Submit Comments and For Further Information: To obtain a copy of
the data collection plans and instruments, submit comments in writing,
or request more information on the proposed project, contact: Janet S.
de Moor, Ph.D., MPH, Project Officer, Division of Cancer
[[Page 72078]]
Control and Population Sciences, 9609 Medical Center Drive, 3E438, MSC
9764, Rockville, MD, 20850 or call non-toll-free number 240-276-6806 or
Email your request, including your address to: janet.demoor@nih.gov.
Formal requests for additional plans and instruments must be requested
in writing.
Comment Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 60 days
of the date of this publication.
Proposed Collection: The National Physician Survey of Precision
Medicine in Cancer Treatment 0925-NEW, National Cancer Institute (NCI),
National Institutes of Health (NIH).
Need and Use of Information Collection: The purpose of this study
is to investigate the current practice of precision medicine in cancer
treatment among medical oncologists in the U.S. This is a nationally
representative survey designed to assess oncologists' current and
potential use of genomic testing, to inform the development of
interventions to facilitate optimal use of genomic testing and to
improve patient-physician discussions of the risks, possible benefits,
and uncertainties surrounding the use of these tests. Current knowledge
of this topic is limited as there are no nationally-representative
studies on this topic to date. There are only two non-federal studies
two that have examined physicians' knowledge and attitudes regarding
somatic genetic and genomic testing. The survey will be administered by
mail and web to approximately 1,630 oncology physicians across the U.S.
Non-respondents will be invited to complete a follow-back survey to
share their reasons for not participating. The study findings will
inform NCI of relevant issues and concerns relating to the application
of precision medicine to current and future cancer treatment patterns
and practice. This information will also inform the development of new
funding initiatives to optimize the use of precision medicine in cancer
treatment. Additionally, information collected as part of this survey
will be used to develop physician educational materials to address
barriers to precision medicine in cancer care delivery.
OMB approval is requested for 2 years. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 261.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Form name Type of Number of responses per per response Total annual
respondent respondents respondent (in hours) burden hour
----------------------------------------------------------------------------------------------------------------
Precision Medicine Survey-- Oncology 175 1 20/60 58
Pilot Study. Physicians.
Precision Medicine Survey-- Oncology 600 1 20/60 200
Full Study. Physicians.
Follow-back Survey............ Oncology 40 1 5/60 3
Physicians.
----------------------------------------------------------------------------------------------------------------
Dated: October 28, 2015.
Karla Bailey,
Project Clearance Liaison, NCI, NIH.
[FR Doc. 2015-29382 Filed 11-17-15; 8:45 am]
BILLING CODE 4140-01-P
